Lantheus Holdings Inc

Research Lantheus Holdings Inc (LNTH) on Bullrun: valuation model: 0.5% overvalued, market cap USD 7.13B, P/E 26.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLNTH
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal0.5% overvalued
• Market capUSD 7.13B
• P/E26.4
• Financial periodFY2025
• RevenueUSD 1.54B
• Revenue growth0.5%
• Net incomeUSD 233.56M
• Gross margin61.1%

Valuation Snapshot

Bullrun's latest valuation model marks Lantheus Holdings Inc as 0.5% overvalued; latest market cap is USD 7.13B; P/E is 26.4.

About Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function;

Frequently asked questions

Is Lantheus Holdings Inc overvalued or undervalued?

Bullrun's valuation model currently marks Lantheus Holdings Inc as 0.5% overvalued.

What is Lantheus Holdings Inc's market cap?

Lantheus Holdings Inc's market capitalization is USD 7.13B.

What is Lantheus Holdings Inc's P/E ratio?

Lantheus Holdings Inc's price-to-earnings (P/E) ratio is 26.4.

What does Lantheus Holdings Inc do?

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.